BioInvent International AB 2025 AR2
The report highlights BioInvent's clinical and strategic progress in 2025, focusing resources on its lead programs BI-1808 and BI-1206. The company advanced these candidates into Phase 2a clinical trials, presenting encouraging efficacy and safety data at major scientific congresses. Financially, BioInvent secured additional funding through a royalty monetization transaction with XOMA Royalty. Operationally, the company achieved ISO 26000 verification, demonstrating its commitment to integrating sustainability into its business strategy and daily operations.
Company: BioInvent International AB
Sector: Health Care
Country: Sweden
Year: 2025
Type: AR2
Pages: 79
Back to company
BioInvent International AB
Annual Report
The report highlights BioInvent's clinical and strategic progress in 2025, focusing resources on its lead programs BI-1808 and BI-1206. The company advanced these candidates into Phase 2a clinical trials, presenting encouraging efficacy and safety data at major scientific congresses. Financially, BioInvent secured additional funding through a royalty monetization transaction with XOMA Royalty. Operationally, the company achieved ISO 26000 verification, demonstrating its commitment to integrating sustainability into its business strategy and daily operations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Renewable Energy
Women on Board
Women in Management
Employees